Tech Transfer eNews Blog
University-Industry Engagement Advisor

U Montreal licenses out technology to help treat liver disease

By Jesse Schwartz
Published: February 27th, 2019

Univalor, the tech transfer arm of the Université de Montréal, has licensed out a technology that could help treat children and adults who suffer from liver disease.

The agreement with Morphocell Technologies aims to commercialize a stem cell-derived liver tissue technology developed by Massimiliano Paganelli at the Centre Hospitalier Universitaire Sainte-Justine, which is affiliated with the Université de Montréal faculty of medicine.

Morphocell plans to integrate the technology in its ReLiver ELT, a regenerative medicine product that can be consistently generated from human pluripotent stem cells.

“Preclinical studies showed that treatment with ReLiver allows us to effectively replace liver functions, decreasing mortality by three times, preventing and treating hepatic encephalopathy, and promoting liver regeneration, without the need of immunosuppression,” says Paganelli.

“Although this has still to be proved in clinical trials,” he adds, “we expect that timely implementation of our stem cell-derived liver tissue through a minimally invasive surgery will restore liver functions while the patient’s liver regenerates, or a suitable organ is found, reducing mortality and relieving morbidity without the need for immunosuppression.”

Bywater Ekegärd, CEO of Morphocell, comments, “We are delighted to have the opportunity to commercialize this groundbreaking technology that will lead the way to revolutionizing how clinicians treat liver disease.”

Source: The Progress

Check out our library of royalty rate references! CLICK HERE

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment